Equities Analysts Set Expectations for HURA Q2 Earnings

TuHURA Biosciences, Inc. (NASDAQ:HURA) – Stock analysts at Zacks Research issued their Q2 2026 earnings estimates for TuHURA Biosciences in a report released on Tuesday, May 26th. Zacks Research analyst J. Vandermosten forecasts that the company will earn ($0.21) per share for the quarter. The consensus estimate for TuHURA Biosciences’ current full-year earnings is ($0.45) per share. Zacks Research also issued estimates for TuHURA Biosciences’ Q3 2026 earnings at ($0.14) EPS, Q4 2026 earnings at $0.16 EPS, FY2026 earnings at ($0.64) EPS, FY2027 earnings at ($0.62) EPS and FY2028 earnings at ($0.52) EPS.

A number of other equities analysts have also recently weighed in on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Tuesday, April 21st. Citizens Jmp assumed coverage on shares of TuHURA Biosciences in a research report on Monday, April 27th. They set a “market outperform” rating and a $9.00 price objective for the company. HC Wainwright restated a “buy” rating and set a $10.00 price objective on shares of TuHURA Biosciences in a research report on Tuesday, February 3rd. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a research report on Wednesday, April 15th. They set a “buy” rating for the company. Finally, Wall Street Zen upgraded shares of TuHURA Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, May 23rd. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $9.00.

TuHURA Biosciences Stock Performance

NASDAQ:HURA opened at $2.38 on Thursday. The company has a fifty day moving average of $2.25 and a two-hundred day moving average of $1.61. The stock has a market capitalization of $151.56 million, a PE ratio of -3.90 and a beta of -0.01. TuHURA Biosciences has a fifty-two week low of $0.41 and a fifty-two week high of $3.90.

TuHURA Biosciences (NASDAQ:HURA) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01).

Institutional Investors Weigh In On TuHURA Biosciences

A number of hedge funds have recently modified their holdings of HURA. Geode Capital Management LLC raised its position in shares of TuHURA Biosciences by 111.4% in the second quarter. Geode Capital Management LLC now owns 582,992 shares of the company’s stock valued at $1,300,000 after buying an additional 307,260 shares during the last quarter. Cetera Investment Advisers acquired a new stake in shares of TuHURA Biosciences in the first quarter valued at about $251,000. WealthShield Partners LLC acquired a new stake in shares of TuHURA Biosciences in the first quarter valued at about $164,000. Deutsche Bank AG raised its position in shares of TuHURA Biosciences by 209.8% in the fourth quarter. Deutsche Bank AG now owns 79,816 shares of the company’s stock valued at $61,000 after buying an additional 54,051 shares during the last quarter. Finally, New York State Common Retirement Fund acquired a new stake in shares of TuHURA Biosciences in the second quarter valued at about $97,000. 0.62% of the stock is currently owned by institutional investors and hedge funds.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company’s core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA’s approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.